OptimizeRx OPRX Estimates

NASDAQ OPRX
$7.87 -0.08 (-1.01%)
At close: Sep 4, 2026 · 4:00 PM EDT
Analyst Estimates

OptimizeRx Corp Revenue Estimates

Periods 18
Next Period Q3 26
Consensus 20.71 M

Analysts expect OptimizeRx Corp to report revenue of 20.71 M for Q3 26, against a range of 19.69 M to 21.73 M. The most recent reported quarter, Q2 26, came in at 20.50 M, a 3.2% miss against the 21.19 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 21.31 M32.32 M21.93 M29.20 M26.07 M32.24 M19.84 M20.50 M--------
High Estimate 25.41 M34.91 M19.51 M25.02 M26.81 M31.89 M18.84 M22.46 M21.73 M38.83 M24.06 M22.37 M22.44 M39.37 M25.55 M21.93 M
Low Estimate 21.84 M29.65 M16.25 M21.34 M22.91 M26.64 M17.16 M19.92 M19.69 M32.31 M21.76 M19.61 M20.77 M34.16 M21.51 M20.47 M
Consensus Estimate 23.63 M32.28 M17.88 M23.18 M24.86 M29.27 M18.00 M21.19 M20.71 M35.57 M22.91 M20.99 M21.60 M36.76 M23.53 M21.20 M
Analyst Estimates

OptimizeRx Corp Earnings Per Share (EPS) Estimates

Periods 18
Next Period Q3 26
Consensus 0.19

Analysts expect OptimizeRx Corp to report earnings per share of 0.19 for Q3 26, against a range of 0.18 to 0.20. The most recent reported quarter, Q2 26, came in at 0.16, a 33.3% beat against the 0.12 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 0.120.300.080.240.200.510.140.16--------
High Estimate 0.060.30-0.120.020.040.240.050.130.200.460.160.150.200.520.170.21
Low Estimate 0.060.26-0.120.020.040.220.050.110.180.380.140.130.160.480.150.17
Consensus Estimate 0.060.28-0.120.020.040.230.050.120.190.420.150.140.180.500.160.19